Bionano Genomics reported a significant 35% decrease in Q3 2024 revenue compared to the previous year, primarily due to a write-down of aged receivables. However, the company showed growth in its core business with a 22% increase in the installed base of optical genome mapping systems and a 27% increase in flowcell sales.